Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A Real World Evaluation of the safety and immunogenicity of the Covishield vaccine, ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant) in Health Care Workers (HCW) in National Capital Region (NCR) of India: A preliminary report

Sushila Kataria, Pooja Sharma, Vikas Deswal, Kuldeep Kumar, Manish Singh, Sazid Alam, Vaibhav Gupta, Padam Singh, Rashmi Phogat, Smita Sarma, Nipun Patil, Rohit Dutt, Renu Saxena, Naresh Trehan
doi: https://doi.org/10.1101/2021.04.14.21255452
Sushila Kataria
1Internal Medicine, Medanta- The Medicity, Gurugram, Haryana, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: drsushilakataria@gmail.com
Pooja Sharma
2Medanta Institute of Education and Research, Gurugram, Haryana, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vikas Deswal
1Internal Medicine, Medanta- The Medicity, Gurugram, Haryana, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kuldeep Kumar
3Medanta Institute of Education and Research, Gurugram, Haryana, India, and PhD Scholar GD Goenka University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manish Singh
3Medanta Institute of Education and Research, Gurugram, Haryana, India, and PhD Scholar GD Goenka University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sazid Alam
4Medanta- The Medicity, Gurugram, Haryana, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vaibhav Gupta
1Internal Medicine, Medanta- The Medicity, Gurugram, Haryana, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Padam Singh
2Medanta Institute of Education and Research, Gurugram, Haryana, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rashmi Phogat
5Department of Microbiology, Medanta- The Medicity, Gurugram, Haryana, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Smita Sarma
5Department of Microbiology, Medanta- The Medicity, Gurugram, Haryana, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nipun Patil
4Medanta- The Medicity, Gurugram, Haryana, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rohit Dutt
6School of Medical and Allied Sciences, GD Goenka University, Gurugram, Haryana, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renu Saxena
7Laboratory Medicine, Medanta- The Medicity, Gurugram, Haryana, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naresh Trehan
4Medanta- The Medicity, Gurugram, Haryana, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The SARS-CoV-2 pandemic has severely impacted health systems, economic and social progress globally in 2020. The rollout of vaccines in several parts of the world is being hailed as a solution to the crisis. With newer and more virulent serotypes on the horizon and limited vaccine available, evaluation of safety and immunogenicity is critical for rationalization of vaccine use in public health.

Objective To evaluate real world safety, and, immunogenicity of the Covishield vaccine, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) in Health Care Workers (HCW) during the national vaccine roll out in the NCR, New Delhi. The safety is evaluated through Adverse Events and Serious Adverse Events reported though enhanced pharmacovigilance protocols, and, the immunogenicity by quantitative determination of anti-S1 and anti-S2 specific IgG antibodies to SARS-CoV-2 in serum samples collected before the receipt of the vaccine and 14 days after dose 1, using the fully automated LIAISON® SARS-CoV-2 S1/S2 IgG test using the chemiluminescence immunoassay (CLIA)

Results In the two weeks after immunization with the Covishield vaccine {ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)}, none of the 1638 evaluated participants reported any serious adverse events (ie require hospitalization or emergency room visit). Solicited adverse events reported via daily diary cards included pain (62.7%) and soreness (24.1%) at injection site as most common, whereas fever (48.4%), headache (43.4%), myalgia (38.4%), fatigue (33.4%), joint pain (27.0%) and nausea (16.0%) were most common solicited systemic adverse events on day 1. Majority of local and systemic adverse events were seen in first 2 days post vaccination and thereafter they resolved. Lesser reactogenicity was observed in subjects with age >50 years. No major difference was observed in adverse events when subjects were stratified based on history of COVID 19 disease or baseline seropositivity. In our study serostatus improved from 48.2% positive at baseline to 79.0% positive 2 weeks following first dose of vaccination. After first dose of vaccination overall higher percentage (98.2%) of seropositivity rates were observed in those with past history of COVID 19 disease

Conclusion The Covishield vaccine {ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)}, was safe and reported mild self limiting adverse events over 2-4 days and had an good early (within 2 weeks) seroresponse. This holds the promise of far reaching impact on vaccine availability for a larger population and thereby providing a widespread coverage.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

CTRI/2021/01/030582

Funding Statement

Medanta Institute of Education and Research

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Medanta Institutional Review Board (MIRB) MICR- 1222/2021

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data is available with the Principal Investigator

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 20, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A Real World Evaluation of the safety and immunogenicity of the Covishield vaccine, ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant) in Health Care Workers (HCW) in National Capital Region (NCR) of India: A preliminary report
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A Real World Evaluation of the safety and immunogenicity of the Covishield vaccine, ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant) in Health Care Workers (HCW) in National Capital Region (NCR) of India: A preliminary report
Sushila Kataria, Pooja Sharma, Vikas Deswal, Kuldeep Kumar, Manish Singh, Sazid Alam, Vaibhav Gupta, Padam Singh, Rashmi Phogat, Smita Sarma, Nipun Patil, Rohit Dutt, Renu Saxena, Naresh Trehan
medRxiv 2021.04.14.21255452; doi: https://doi.org/10.1101/2021.04.14.21255452
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
A Real World Evaluation of the safety and immunogenicity of the Covishield vaccine, ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant) in Health Care Workers (HCW) in National Capital Region (NCR) of India: A preliminary report
Sushila Kataria, Pooja Sharma, Vikas Deswal, Kuldeep Kumar, Manish Singh, Sazid Alam, Vaibhav Gupta, Padam Singh, Rashmi Phogat, Smita Sarma, Nipun Patil, Rohit Dutt, Renu Saxena, Naresh Trehan
medRxiv 2021.04.14.21255452; doi: https://doi.org/10.1101/2021.04.14.21255452

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (420)
  • Anesthesia (97)
  • Cardiovascular Medicine (896)
  • Dentistry and Oral Medicine (169)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (405)
  • Epidemiology (8764)
  • Forensic Medicine (4)
  • Gastroenterology (404)
  • Genetic and Genomic Medicine (1857)
  • Geriatric Medicine (177)
  • Health Economics (387)
  • Health Informatics (1284)
  • Health Policy (642)
  • Health Systems and Quality Improvement (490)
  • Hematology (206)
  • HIV/AIDS (392)
  • Infectious Diseases (except HIV/AIDS) (10543)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1748)
  • Nursing (102)
  • Nutrition (265)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (459)
  • Oncology (962)
  • Ophthalmology (281)
  • Orthopedics (107)
  • Otolaryngology (176)
  • Pain Medicine (117)
  • Palliative Medicine (41)
  • Pathology (263)
  • Pediatrics (556)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (218)
  • Psychiatry and Clinical Psychology (1841)
  • Public and Global Health (3975)
  • Radiology and Imaging (650)
  • Rehabilitation Medicine and Physical Therapy (341)
  • Respiratory Medicine (534)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (196)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (79)